Business context and reporting period
Filing identity: The supplied filing is Proteon Therapeutics, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2015—not a filing under the name Protara Therapeutics, Inc. Investors should verify the issuer and filing metadata.
Proteon was a development-stage biopharmaceutical company focused on renal and vascular disease. Its lead candidate, vonapanitase (formerly PRT-201), was in Phase 3 development to reduce failure of radiocephalic arteriovenous fistulas (AVFs) used for hemodialysis. The company had no product sales.
Financial results and liquidity
Amounts below are in U.S. dollars; financial statement amounts are in thousands except per-share data.
| Metric | Q1 2015 | Q1 2014 / comparison |
|---|---|---|
| Revenue | No revenue reported in the statements | No product revenue; historical revenue sources included grants and a prior agreement |
| Research and development expense | $2.633 million | $1.189 million |
| General and administrative expense | $1.987 million | $0.744 million |
| Total operating expenses | $4.620 million | $1.933 million |
| Operating loss | $4.620 million | $1.933 million |
| Net loss | $4.580 million | $2.831 million |
| Net loss per share | $0.28 | $18.09; prior-period share count reflects the pre-IPO capital structure and reverse-split-adjusted presentation |
| Cash used in operating activities | $3.873 million | $1.562 million |
| Cash and cash equivalents | $9.784 million at March 31 | $68.840 million at December 31, 2014 |
| Available-for-sale investments | $69.741 million at March 31 | $14.755 million at December 31, 2014 |
| Total cash, cash equivalents and investments | $79.519 million | $83.595 million at December 31, 2014 |
| Total current liabilities | $2.634 million | $2.338 million at December 31, 2014 |
| Total liabilities | $2.634 million | $2.338 million at December 31, 2014 |
There was no debt reported at quarter-end; convertible notes had converted into preferred stock in May 2014. No operating margin is meaningful because the company reported no product revenue. Accumulated deficit was $114.454 million. The company reported no significant income tax provision or benefit.
Material changes versus the prior comparable period
- Net loss increased $1.749 million year over year as operating expenses rose $2.687 million, partly offset by the absence of prior-year interest and other expenses related to converted notes and associated derivative features.
- R&D expense rose $1.444 million, mainly from higher external clinical costs: increased spending on the ongoing Phase 3 AVF trial and preparation for the second trial. G&A expense rose $1.243 million, reflecting added personnel and overhead and public-company costs.
- Operating cash use increased $2.311 million. Investing cash outflow was $55.183 million, primarily because $58.139 million was invested in available-for-sale securities; this largely shifted funds out of cash rather than representing operating burn.
- Total cash, cash equivalents and investments declined about $4.076 million from year-end, while the mix shifted substantially from cash into short-term investments. The company reported a $6,000 unrealized gain on available-for-sale investments in the quarter.
Outlook, commentary, risks and unusual items
- Management expected existing cash, cash equivalents and investments to fund operations and capital expenditures into 2018, including results from the first Phase 3 trial, commencement of the second trial and CMC activities. However, the risk-factor discussion says current resources were not expected to fund completion of the second Phase 3 trial; additional funding may therefore be needed.
- The second Phase 3 radiocephalic AVF trial was expected to begin in Q2 2015. The company said it might discuss filing a BLA after one Phase 3 trial if results were sufficiently compelling, but acknowledged the FDA could require the second or additional trials.
- A key clinical uncertainty: the Phase 2 primary endpoint did not show statistically significant benefit for the 30-microgram dose versus placebo. The favorable radiocephalic AVF subset findings were not prespecified and may not be reproduced in Phase 3.
- Management expected losses and R&D spending to increase for the foreseeable future. The company had no commercial manufacturing facilities or sales organization and relied on third parties for manufacturing and clinical trials.
- Risks include Phase 3 efficacy, safety, enrollment and regulatory uncertainty; additional financing and potential dilution; manufacturing and supplier dependence; reimbursement and commercialization challenges; intellectual-property exposure; and foreign-exchange risk. The Lonza API contract was denominated in Swiss francs, and the filing cited increased currency volatility after the Swiss National Bank’s January 2015 policy change. The company had not hedged currency exposure.
- The filing disclosed a prior FDA Warning Letter to finished-product supplier Jubilant HollisterStier; the FDA had stated that it did not affect the batch intended for Phase 3 trials. The company also disclosed a Johns Hopkins license royalty of 2.5% of net product sales once sales commence.
- No material subsequent events or material litigation were reported. Management concluded disclosure controls were effective at the reasonable-assurance level and reported no material change in internal control over financial reporting during the quarter.
Most important facts for investors to verify
- Confirm the issuer: the filing identifies Proteon Therapeutics, Inc., despite the request metadata naming Protara Therapeutics, Inc.
- Check subsequent disclosures for the first and second Phase 3 trial timelines, enrollment, results and any FDA discussions about a single-trial BLA.
- Reconcile the stated runway into 2018 with management’s warning that available funds may not cover completion of the second Phase 3 trial; review financing needs and any dilution.
- Assess whether the non-prespecified Phase 2 subset signal is supported by prespecified Phase 3 endpoints and whether safety or formulation issues emerge.
- Monitor availability and compliance of contract manufacturing, including supplier concentration, CMC validation and the disclosed prior supplier warning letter.